PPT-Ibrutinib: Analysis of Pivotal Data

Richard R Furman MD CLL Research Center BCRassociated Kinases Proven Effective Therapeutic Targets Nat Rev Immunol 2945 Syk spleen tyrosine kinase fostamatinib PRT062070 GS9973 Btk Brutons . Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . Statistical discourse analysis . of a role-based online discussion. . To appear in the . International Journal of Computer-Supported Collaborative Learning. Alyssa Wise. Simon Fraser University alyssa_wise@sfu.cas. . lymfom. Från. indolent till aggressive . sjukdom. Del 1 . Birgitta. Sander . patologi. och . biologi. Del 2 Anna Laurell . klinik. och . terapi. MCL indolent till aggressive . sjukdom. Indolent. New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . and. Strategies Across the Product Lifecycle . What’s Included in this deck. Definition of Strategy. Why create a strategy statement?. Elements to consider in crafting a strategy. Strategy statement template. Presented By John Byrd at 2014 ASCO Annual Meeting. Background. Presented By John Byrd at 2014 ASCO Annual Meeting. RESONATE™ Phase 3 Study Design. Presented By John Byrd at 2014 ASCO Annual Meeting. Business Case Presentation Components. Why are we considering this proposal?. Strategic alignment. Opportunity summary. Problem; market analysis. Value proposition . Solution overview. Competitive overview; product positioning. . A Brief Update of an Ongoing Trial. Jeff Jones, MD, MPH. 16 May 2015. 2. P. LYN. BCR. CD79a. CD79b. SYK. BTK. PLC. γ. IBRUTINIB. GROWTH. SURVIVAL. B-cell Receptor is the “Accelerator” of B-cells. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Therapeutic Targets in CLL. Venetoclax in Patients With 17p Deletion. Venetoclax in Patients With 17p Deletion (cont). Bendamustine Plus Obinutuzumab. Ibrutinib Plus Ublituximab. Updates in Lymphoma From Recent Congresses. Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP Clinical Pharmacy Specialist, Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Panelist Matthew Snyder, PharmD, BCOP Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . Davids. , MD, . MMSc. . Disclosures for . Ms. . Montegaard. Advisory Committee . Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company . Consulting Agreements . Jean . Shimer. . and Patti . Fougere. , MA Part C. Karen Walker, WA Part . C. Karie. Taylor, AZ Part C. Abby . Winer, . DaSy. , ECTA. Tony Ruggiero, . DaSy. , . IDC. 2014 Improving Data, Improving Outcomes Conference.